These authors contributed equally to this work.
Article first published online: 26 APR 2013
Copyright © 2013 American Association for the Study of Liver Diseases
Volume 57, Issue 6, pages 2135–2142, June 2013
How to Cite
Yu, M.-L., Lee, C.-M., Chen, C.-L., Chuang, W.-L., Lu, S.-N., Liu, C.-H., Wu, S.-S., Liao, L.-Y., Kuo, H.-T., Chao, Y.-C., Tung, S.-Y., Yang, S.-S., Kao, J.-H., Su, W.-W., Lin, C.-L., Yang, H.-C., Chen, P.-J., Chen, D.-S., Liu, C.-J. and for the Taiwan Liver-Net Consortium (2013), Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology, 57: 2135–2142. doi: 10.1002/hep.26266
Potential conflict of interest: Nothing to report.
This study was supported in part by grants from the Department of Health, National Science Council (100-2325-B-002-052 and 101-2325-B-002-073, Resource Center, National Research Program for Biopharmaceuticals), Executive Yuan, Taiwan; and National Taiwan University, Taiwan.
Results of this study were presented at the 22nd Conference of the Asian Pacific Association for the Study of the Liver, Taipei, Taiwan, February 16-19, 2012, and at the 47th Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain, April 18-22, 2012.
- Issue published online: 12 JUN 2013
- Article first published online: 26 APR 2013
- Accepted manuscript online: 15 JAN 2013 03:09PM EST
- Manuscript Accepted: 20 DEC 2012
- Manuscript Received: 16 AUG 2012
Patients dually infected with hepatitis C virus (HCV)/hepatitis B virus (HBV) have a higher risk of developing advanced liver disease or hepatocellular carcinoma compared with monoinfected patients. Yet, there is a similar rate of sustained virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy in these patients compared with HCV-monoinfected patients and a high hepatitis B surface antigen (HBsAg) seroclearance rate. The durability of hepatitis C and B clearance in coinfected patients was investigated in a 5-year follow-up study. Patients with active HCV genotype 1, both HBV-coinfected (n = 97) and HBV-monoinfected (n = 110), underwent 48-week combination therapy with peginterferon alfa-2a plus ribavirin. In patients with active HCV genotype 2 or 3, both HBV-coinfected (n = 64) and monoinfected (n = 50) patients underwent 24-week combination therapy. A total of 295 (91.9%) patients completed treatment and 24 weeks posttreatment follow-up; 264 (89.5%) patients agreed to receive additional follow-up for up to 5 years after the end of treatment. After a median follow-up of 4.6 ± 1.0 years, six of the 232 patients achieving SVR developed HCV RNA reappearance, including five HCV genotype 1/HBV-coinfected patients and one HCV genotype 2/3-monoinfected patient. Subgenomic analysis of the HCV core gene indicated that five patients developed delayed recurrence of HCV infection. Overall, the cumulative recurrence rate of HCV infection was 2.3% (0.4%/year; 95% confidence interval [CI], 0.9%-5.5%). The cumulative HBsAg seroclearance rate was 30.0% (95% CI, 21.5%-42.0%); with 33.1% (95% CI, 21.8%-50.1%) in the 48-week combination therapy group and 24.3% (95% CI, 13.7%-42.9%) in the 24-week therapy group. Conclusion: Peginterferon alfa-2a and ribavirin therapy provides good HCV SVR durability and a high accumulative HBsAg seroclearance rate in patients who are coinfected with HCV and HBV. (HEPATOLOGY 2013;)